Repare Therapeutics Inc (RPTX) NPV

Sell:$1.17Buy:$1.18$0.03 (2.61%)

NASDAQ:0.31%
Prices delayed by at least 15 minutes
Sell:$1.17
Buy:$1.18
Change:$0.03 (2.61%)
Prices delayed by at least 15 minutes
Sell:$1.17
Buy:$1.18
Change:$0.03 (2.61%)
Prices delayed by at least 15 minutes

Company Information

About this company

Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.

Key people

Lloyd M. Segal
President, Chief Executive Officer, Director
Steve Forte
Chief Financial Officer, Executive Vice President
Michael Zinda
Executive Vice President, Chief Scientific Officer
Maria Koehler
Executive Vice President, Chief Medical Officer
Thomas Civik
Independent Chairman of the Board
David P. Bonita
Independent Director
Samarth Kulkarni
Independent Director
Susan M. Molineaux
Independent Director
Ann D. Rhoads
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Canada
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US7602731025
  • Market cap
    $48.89m
  • Employees
    179
  • Shares in issue
    42.51m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.